Sponsor
Celltrion Healthcare Australia
17 PBAC submissions on file, active 2019–2025. 88% have been recommended.
Submissions
17
2019 → 2025
Win rate
88 %
15 recommended of 17 bucketable
Drugs
11 · 10 listed
unique molecules submitted
PBS spend captured
$857M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Aflibercept
Ophthalmology · Recommended · 2025 $414M Denosumab
Endocrinology · Recommended · 2025 $291M Infliximab
Rheumatology · Recommended with restriction · 2025 $88M Bevacizumab
Oncology · Recommended · 2024 $63M Adalimumab
Rheumatology · Recommended with restriction · 2024 other sponsor Trastuzumab
Oncology · Recommended · 2021 — Omalizumab
Immunology · Recommended with restriction · 2025 other sponsor Pioglitazone
Endocrinology · Recommended · 2025 — Rituximab
Haematology · Recommended · 2021 other sponsor Tocilizumab
Rheumatology · Noted · 2025 other sponsor Ustekinumab
Dermatology · Recommended · 2025 other sponsor Therapy area mix Rheumatology 7 Oncology 4 Endocrinology 2 Gastroenterology 1 Ophthalmology 1 Respiratory 1 Immunology 1
Activity by year 2019 (2) · 2020 (1) · 2021 (1) · 2022 (3) · 2024 (3) · 2025 (7)
Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.